OverviewSuggest Edit

MacroGenics, Inc. is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops new therapeutic product candidates using its antibody-based technology platforms and also in partnership with other biopharmaceutical companies. MacroGenics has a pipeline of product candidates in human clinical testing, primarily against various cancers. These include two product candidates developed using Fc Optimization platform, namely margetuximab, an antibody for the treatment of certain types of metastatic breast cancers and gastroesophageal cancers, and MGA271, an antibody to impact various tumors through multiple potential mechanisms of action. In addition, the Company has created different product candidates based on Dual-Affinity Re-Targetingr (DART) platform.

TypePublic
Founded2000
HQRockville, MD, US
Websitemacrogenics.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Feb 2020)384(+6%)
Job Openings25
Revenue (FY, 2020)$104.9 M(+64%)
Share Price (Sept 2021)$27.2
Cybersecurity ratingCMore

Key People/Management at MacroGenics

Scott Koenig

Scott Koenig

President and CEO and Director
Paulo Costa

Paulo Costa

Chairman
James Karrels

James Karrels

SVP, CFO
Karen Ferrante

Karen Ferrante

Director
Ezio Bonvini

Ezio Bonvini

Senior Vice President, Research and Chief Scientific Officer
Stephen Eck

Stephen Eck

Senior Vice President, Clinical Development & Chief Medical Officer
Show more

MacroGenics Office Locations

MacroGenics has offices in Rockville and Brisbane
Rockville, MD, US (HQ)
9640 Medical Center Dr
Brisbane, CA, US
3280 Bayshore Blvd #200
Rockville, MD, US
15235 Shady Grove Rd
Show all (3)

MacroGenics Financials and Metrics

MacroGenics Revenue

MacroGenics's revenue was reported to be $104.88 m in FY, 2020
USD

Revenue (Q1, 2021)

16.9m

Gross profit (Q1, 2021)

16.9m

Gross profit margin (Q1, 2021), %

99.9%

Net income (Q1, 2021)

(51.3m)

EBIT (Q1, 2021)

(51.3m)

Market capitalization (14-Sept-2021)

1.6b

Closing stock price (14-Sept-2021)

27.2

Cash (31-Mar-2021)

218.5m

EV

1.4b
MacroGenics's current market capitalization is $1.6 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

58.0m47.8m100.9m91.9m157.7m60.1m64.2m104.9m

Revenue growth, %

(18%)111%(9%)

General and administrative expense

11.1m15.9m22.8m29.8m32.7m40.5m46.1m42.7m

R&D expense

46.6m70.2m98.3m122.1m147.2m190.8m195.3m193.2m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

20.2m14.7m9.2m18.4m71.3m6.7m14.7m2.8m80.7m3.3m2.1m1.7m1.7m4.7m18.8m20.8m9.7m10.0m18.0m13.7m15.6m17.4m16.9m

Cost of goods sold

17.0k

Gross profit

16.9m

Gross profit Margin, %

100%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

116.5m157.6m196.2m84.1m211.7m126.5m181.1m

Accounts Receivable

2.0m2.9m1.2m2.8m13.6m12.7m23.1m

Prepaid Expenses

971.7k4.2m1.8m3.2m11.3m17.0m

Inventories

Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

33.6m198.7m194.0m179.2m263.1m235.0m365.8m152.0m62.3m109.9m40.5m116.6m90.9m200.4m238.7m201.8m238.6m180.3m156.6m93.1m196.5m201.6m218.5m

Accounts Receivable

2.3m1.7m2.6m5.3m1.7m4.3m2.7m2.5m78.4m3.0m2.1m2.0m2.2m7.3m17.8m21.0m6.1m5.6m9.5m11.8m19.2m18.8m7.1m

Prepaid Expenses

2.1m2.5m3.6m3.1m2.0m1.7m3.8m1.3m5.0m4.0m3.3m3.3m3.2m8.3m9.6m12.0m12.6m8.2m10.6m18.2m

Inventories

6.2m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(260.8k)(38.3m)(20.1m)(58.5m)(19.6m)(171.5m)(151.8m)(129.7m)

Depreciation and Amortization

1.2m1.8m2.9m7.6m7.2m8.3m10.8m12.0m

Accounts Payable

(570.1k)(1.5m)(163.0k)2.2m(1.5m)1.6m787.0k3.7m

Cash From Operating Activities

(14.2m)(32.8m)(13.7m)(43.7m)14.4m(153.2m)(134.3m)(111.9m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

2.9m(3.1m)(15.4m)(19.3m)45.1m23.8m8.3m(30.4m)10.1m(23.7m)(37.7m)(78.3m)(125.4m)(49.5m)(92.8m)(126.8m)(45.0m)(76.8m)(121.4m)(44.7m)(91.6m)(127.7m)(51.3m)

Depreciation and Amortization

834.6k398.2k835.0k1.3m546.0k1.2m1.7m1.8m3.6m5.6m2.0m4.0m5.9m1.3m2.5m5.3m2.9m5.5m8.1m2.8m6.1m9.1m2.7m

Inventories

(6.2m)

Accounts Payable

(1.9m)2.0m808.0k1.2m(225.0k)184.0k872.0k(388.0k)(355.0k)(133.0k)(2.2m)(2.0m)(2.1m)7.8m(684.0k)(1.5m)(2.5m)(2.6m)(913.0k)(2.3m)(1.5m)137.0k1.8m
USDQ3, 2013

Financial Leverage

-10.4 x
Show all financial metrics

MacroGenics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

74/100

SecurityScorecard logo

MacroGenics Online and Social Media Presence

Embed Graph

MacroGenics News and Updates

MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress

ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced poster presentations relating to multiple investi…

: MacroGenics stock falls after study shows breast-cancer survival rates for drug didn’t surpass standard treatment

MacroGenics Inc. MGNX shares dropped late Tuesday after the biotech drug developer said its breast-cancer treatment didn’t perform as well as standard treatment in a late-stage clinical study. MacroGenics shares, which had been halted after hours, dropped as much as 20% in the extended session after…

MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer

ROCKVILLE, MD, Sept. 07, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the final overall survival (OS) results of the SO…

MacroGenics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses

MacroGenics and Zai Lab Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology

ROCKVILLE, MD, SHANGHAI and SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) --   MacroGenics (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal-antibody-based therapeutics for the treatment of cancer, and Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9…

Zai Lab and MacroGenics Enter Into Broad Strategic Collaboration to Develop and Commercialize Preclinical Bispecific Antibodies in Oncology

SHANGHAI, SAN FRANCISCO and ROCKVILLE, MD, June 16, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and MacroGenics (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monocl…
Show more

MacroGenics Blogs

MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results

Upcoming MGC018 and margetuximab MAHOGANY clinical data presentations at European Society for Medical Oncology (ESMO) Meeting Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md. , July 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics , Inc. (NASDAQ: MGNX), a biopharmaceutical company

MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call

ROCKVILLE, MD , July 22, 2021 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial

MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results

MARGENZA™ launched in mid-March Upcoming poster presentation of MGC018 initial Phase 1 clinical data at ASCO Conference call scheduled for today at 4:30 p.m. ET. ROCKVILLE, Md. , April 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing

MacroGenics Provides Update on Corporate Progress and 2020 Financial Results

MacroGenics Provides Update on Corporate Progress and 2020 Financial Results Content Import Thu, 02/25/2021 - 16:04 MacroGenics Provides Update on Corporate Progress and 2020 Financial Results Feb 25, 2021 This release is a backfill from a News Wire …

MacroGenics Announces MGD019 Publication in Cell Reports Medicine

MacroGenics Announces MGD019 Publication in Cell Reports Medicine Content Import Tue, 12/22/2020 - 11:35 MacroGenics Announces MGD019 Publication in Cell Reports Medicine Dec 22, 2020 This release is a backfill from a News Wire General …

MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® ( trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial MARGENZA is approved, in combination with chemotherapy, for the treatment of
Show more

MacroGenics Frequently Asked Questions

  • When was MacroGenics founded?

    MacroGenics was founded in 2000.

  • Who are MacroGenics key executives?

    MacroGenics's key executives are Scott Koenig, Paulo Costa and James Karrels.

  • How many employees does MacroGenics have?

    MacroGenics has 384 employees.

  • What is MacroGenics revenue?

    Latest MacroGenics annual revenue is $104.9 m.

  • What is MacroGenics revenue per employee?

    Latest MacroGenics revenue per employee is $273.1 k.

  • Who are MacroGenics competitors?

    Competitors of MacroGenics include EMS Pharma, Cipla and PPD.

  • Where is MacroGenics headquarters?

    MacroGenics headquarters is located at 9640 Medical Center Dr, Rockville.

  • Where are MacroGenics offices?

    MacroGenics has offices in Rockville and Brisbane.

  • How many offices does MacroGenics have?

    MacroGenics has 3 offices.